stockrow
Friday 6 November 2026
Export ORGO’s income statement to Excel — free account
Organogenesis
ORGO Healthcare Drug Manufacturers Specialty & Generic
Organogenesis' revenue for fiscal 2025 (year ended December 2025) was $564.2 million, up 17.0% from fiscal 2024.
- Revenue
- −69.9%
- EPS
- −327.3%
- Free cash flow
- −2,048.8%
- Total debt
- +395.3%
Quarter to September 2026, against a year earlier
0.89
0.05
+5.95%
Follow ORGO
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 57.56 |
+8 more quarters Free account |
P/S ratio |
0.50 | 0.68 | 0.59 | 1.16 | |
P/FCF ratio |
49.81 | 15.00 | 17.73 | 0.00 | |
P/Operating CF |
(9.50) | (9.88) | 14.34 | 16.65 | |
P/B ratio |
1.48 | 2.11 | 1.24 | 2.19 | |
Price to Tangible BV |
2.00 | 2.68 | 1.43 | 2.50 | |
EV/Sales |
0.47 | 0.62 | 0.45 | 1.03 | |
EV/EBITDA |
0.00 | 0.00 | 6.44 | 8.11 | |
EV/Operating CF |
16.13 | 8.84 | 7.45 | (56.35) | |
EV/FCF |
46.82 | 13.56 | 13.41 | (23.75) | |
Quick Ratio |
2.51 | 2.59 | 2.75 | 3.11 | |
Current Ratio |
3.32 | 3.52 | 3.53 | 3.62 | |
Net Debt/EBITDA |
0.00 | 0.81 | 1.41 | (1.16) | |
Debt/Assets |
2.81% | 2.66% | 2.38% | 2.14% | |
Debt/Equity |
0.09 | 0.07 | 0.05 | 0.04 | |
Asset Turnover |
0.80 | 1.05 | 1.04 | 1.03 | |
Operating CF/Net income |
0.57 | 0.32 | (0.38) | 1.12 | |
Capex/Depreciation |
0.00 | (0.17) | (0.25) | (0.66) | |
Research and Development Expense of Revenue |
17.51% | 41.82% | 40.72% | 4.56% | |
Selling, General and Administrative Expense of Revenue |
99.19% | 123.33% | 175.10% | 44.40% | |
Intangible Assets out of Total Assets |
0.09 | 0.08 | 0.06 | 0.06 | |
Share Based Compensation of Revenue |
6.17% | 6.98% | 9.77% | 1.92% | |
Graham Net Nets |
(0.52) | (0.19) | (0.02) | 0.10 | |
Graham Number |
0.00 | 0.00 | 0.00 | 2.19 | |
Earnings Yield |
(88.32%) | (34.98%) | (7.59%) | 1.74% | |
Free Cash Flow Yield |
2.01% | 6.66% | 5.64% | (3.73%) | |
Revenue per Share |
0.35 | 0.34 | 0.29 | 1.78 | |
Operating CF per Share |
(0.14) | (0.25) | 0.17 | 0.31 | |
Capex per Share |
0.02 | (0.01) | (0.02) | (0.04) | |
Free Cash Flow per Share |
(0.13) | (0.25) | 0.14 | 0.27 | |
Cash per Share |
0.21 | 0.36 | 0.72 | 0.74 | |
Shareholders Equity per Share |
0.93 | 1.15 | 1.91 | 2.37 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.93 | 1.15 | 1.91 | 2.37 | |
Free Cash Flow |
(16.45) | (32.75) | 17.98 | 34.77 | |
Working Capital |
110.48 | 143.34 | 192.48 | 262.06 | |
Capital Expenditures |
2.15 | (1.10) | (3.15) | (4.65) | |
Net Current Asset Value |
(91.04) | (57.88) | (6.94) | 63.59 | |
EV/EBIT |
0.00 | 0.00 | 89.88 | 13.00 | |
Capex to Sales |
(0.05) | 0.03 | 0.08 | 0.02 | |
Price to Operating Income |
0.00 | 0.00 | 118.82 | 14.69 | |
| Other line items | |||||
Average Receivables |
130.74 | 110.66 | 110.11 | 163.66 | |
Average Payables |
31.35 | 29.51 | 26.64 | 30.43 | |
Average Inventory |
33.13 | 31.16 | 28.88 | 27.92 | |
Average Assets |
439.37 | 433.79 | 493.69 | 548.31 | |
Average Common Equity |
187.43 | 190.76 | 243.73 | 281.51 |
Columns are period end dates · fundamentals updated 5 Nov 2026